Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Feliu, Jaime ^a   Salud, Antonieta ^b   Safont, Maria J ^c   García Girón, Carlos ^d   Aparicio, Jorge ^e   Losa, Ferran ^f   Bosch, Carlos ^g   Escudero, Pilar ^h   Casado, Enrique ⁱ   Jorge, Monica ^j   Bohn, Uriel ^k   Pérez Carrión, Ramon ^l   Carmona, Alberto ^m   Custodio, Ana B ^a   Maurel, Joan ⁿ  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f Hospital Cruz Roja   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^j Servicio de Oncologia   (Spain)

^k HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^l Hospital Universitario Quiron Madrid   (Spain)

^m HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁿ HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL RATE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL RESPONSE RATE; OVERALL SURVIVAL; PHARMACOLOGICAL PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEINURIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; COMPLICATION; DISEASE FREE SURVIVAL; MULTIVARIATE ANALYSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAPECITABINE; CLINICAL TRIALS, PHASE II AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; HYPERTENSION; MALE; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PROTEINURIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84928884000     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116527     Document Type: Article

References (29)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, et al. (2013) Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49:1374-1403. doi: 10.1016/j.ejca.2012.12.027 PMID: 23485231
2. Cancer Research UK. Bowel cancer incidence statistics. Available: http://www.cancerresearchuk.org/prod-consump/groups/cr-common/@cah/@gen/documents/generalcontent/about-bowel-cancer.pdf.pdf. Accessed 2014 Jul. 10.
3. McKibbin T, Frei CR, Greene RE, Kwan P, Simon J, et al. (2008) Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist 13:876-885. doi: 10.1634/theoncologist.2008-0061 PMID: 18695260
4. Quipourt V, Jooste V, Cottet V, Faivre J, Bouvier AM (2011) Comorbidities alone do not explain the undertreatment of colorectal cancer in older adults: a French population-based study. J Am Geriatr Soc 59:694-698. doi: 10.1111/j.1532-5415.2011.03334.x PMID: 21438864
5. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, et al. (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23:2479-2516. doi: 10.1093/annonc/mds236 PMID: 23012255
6. Tahover E, Uziely B, Salah A, Temper M, Peretz T, et al. (2013) Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 30:327. doi: 10.1007/s12032-012-0327-4 PMID: 23254964
7. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S (2011) Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 68:1207-1213. doi: 10.1007/s00280-011-1604-1 PMID: 21409384
8. Österlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, et al. (2011) Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 104:599-604. doi: 10.1038/bjc.2011.2 PMID: 21304526
9. Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, et al. (2012) Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One 7:e38364. doi: 10.1371/journal.pone.0038364 PMID: 22719881
10. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28:949-954. doi: 10.1200/JCO.2009.25.4482 PMID: 20085937
11. Feliu J, Safont MJ, Salud A, Losa F, García-Girón C, et al. (2010) Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 102:1468-1473. doi: 10.1038/sj.bjc.6605663 PMID: 20424611
12. Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, et al (2014) First-line bevacizumab and capecitabineoxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. Br J Cancer 111:241-248. doi: 10.1038/bjc.2014.346 PMID: 24946000
13. Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, et al. (2011) An observational study of bevacizumabinduced hypertension as a clinical biomarker of antitumor activity. Oncologist 16:1325-1332. doi: 10.1634/theoncologist.2010-0002 PMID: 21807768
14. Dewdney A, Cunningham D, Barbachano Y, Chau I (2012) Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer 106:1718-1721. doi: 10.1038/bjc.2012.152 PMID: 22531628
15. Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, et al. (2013) Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 18:273-280. doi: 10.1634/theoncologist.2012-0339 PMID: 23485622
16. Saloustros E, Androulakis N, Vamvakas L, Mavroudis D, Georgoulias V (2010) Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. Case Rep Oncol 3:368-371. doi: 10.1159/000321630 PMID: 21537380
17. Karachaliou N, Saloustros E, Vamvakas L, Mavroudis D, Georgoulias V (2010) Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer. Ann Oncol 21:1729-1730. doi: 10.1093/annonc/mdq328 PMID: 20601370
18. Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, et al. (2014) Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer 14:184. doi: 10.1186/1471-2407-14-184 PMID: 24628963
19. Iwasa S, Nakajima TE, Nagashima K, Honma Y, Kato K, et al. (2013) Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer. Anticancer Res 33:309-316. PMID: 23267162
20. Laskin J, Crinò L, Felip E, Franke F, Gorbunova V, et al. (2012) Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: Safety of Avastin in Lung Trial (MO19390). J Thorac Oncol 7:203-211. doi: 10.1097/JTO. 0b013e3182370e02 PMID: 22173662
21. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O (2009) Addition of bevacizumab to fluorouracilbased first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27:199-205. doi: 10.1200/JCO.2008.17.7931 PMID: 19064978
22. Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, et al. (2013) XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol 71:257-264. doi: 10.1007/s00280-012-2004-x PMID: 23100174
23. Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, et al. (2010) Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factorsignaling inhibitors. Hypertension 56:1131-1136. doi: 10.1161/HYPERTENSIONAHA.110.160481 PMID: 20956731
24. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, et al. (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707-716. doi: 10. 1172/JCI17423 PMID: 12618525
25. Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, et al. (2012) VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab. An analysis of data from randomized trials AVITA and AVOREN. Lancet Oncol 13:724-733.
26. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, et al. (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678. doi: 10.1200/JCO.2008.16.1612 PMID: 18824714
27. Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, Del Alba AG, et al. (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12:1143-1150. doi: 10.1016/S1470-2045 (11) 70266-2 PMID: 22015057
28. Morita S, Uehara K, Nakayama G, Shibata T, Oguri T, et al. (2013) Association between bevacizumabrelated hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 7:405-411. doi: 10.1007/s00280-012-2028-2
29. Avastin Summary of Product Characteristics. Available: http://www.medicines.org.uk/emc/medicine/15748/SPC/Avastin%2025mg/ml%20concentrate%20for%20solution%20for%20infusion/. Accessed 2014 Jul. 10